Jefferies Financial Group Inc. Acquires Shares of 23,411 Elanco Animal Health Incorporated $ELAN

Jefferies Financial Group Inc. acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, Holdings Channel reports. The firm acquired 23,411 shares of the company’s stock, valued at approximately $530,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Northwestern Mutual Investment Management Company LLC boosted its holdings in Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after purchasing an additional 428 shares in the last quarter. Legacy Capital Group California Inc. boosted its holdings in Elanco Animal Health by 3.1% during the fourth quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company’s stock valued at $475,000 after purchasing an additional 632 shares in the last quarter. AlphaQuest LLC boosted its holdings in Elanco Animal Health by 13.7% during the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after purchasing an additional 718 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after purchasing an additional 798 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in Elanco Animal Health by 1.9% during the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after purchasing an additional 824 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ELAN. KeyCorp upped their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Leerink Partners upped their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $23.86 on Friday. Elanco Animal Health Incorporated has a 1-year low of $13.09 and a 1-year high of $27.72. The firm’s 50-day moving average price is $22.96 and its two-hundred day moving average price is $23.32. The stock has a market capitalization of $11.92 billion, a price-to-earnings ratio of -47.72, a P/E/G ratio of 2.57 and a beta of 1.69. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the prior year, the business earned $0.37 earnings per share. Elanco Animal Health’s quarterly revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.